IBRX261113P00010000
IBRX Nov 13 2026 10.00 Put
optionOPRA
EODOct 15, 2026
1.05USD-12.500%(-0.15)4Vol11OI
Loading…
Underlying
Underlying Price
$8.36
Type
Put
Strike
10
Expiration
Nov 13, 2026
DTE
24d
Moneyness
ITM
Intrinsic
$1.64
IBRX 10 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.93 | +78.85% | 176 | 1,656 |
| Oct 30, 2026 | 10d | $1.15 | +76.92% | 2 | 259 |
| Nov 6, 2026 | 17d | $1.47 | +14.84% | 2 | 125 |
| Nov 13, 2026 | 24d | $1.05 | -12.50% | 4 | 11 |
| Nov 20, 2026 | 31d | $1.48 | +28.70% | 99 | 741 |
| Nov 27, 2026 | 38d | $1.52 | -12.14% | 1 | 1 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $2.06 | +1.48% | 50 | 6,458 |
| Mar 19, 2027 | 150d | $2.40 | -4.00% | 10 | 68 |
| Apr 16, 2027 | 178d | $4.80 | +0.00% | 10 | 17 |
| May 21, 2027 | 213d | $3.00 | -36.17% | 10 | 164 |
| Aug 20, 2027 | 304d | $4.70 | +0.00% | 1 | 16 |
| Nov 19, 2027 | 395d | $2.50 | +0.00% | 1 | 1 |
| Jan 21, 2028 | 458d | $3.50 | +3.24% | 50 | 3,805 |
| Mar 17, 2028 | 514d | $4.00 | -6.32% | 1 | 20 |
| Jan 19, 2029 | 822d | $4.45 | +7.23% | 1 | 89 |
IBRX Nearby Strikes · Nov 13, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 7 P | $0.20 | -60.00% | 800 | 1,105 | OTM |
| 7.5 P | $0.28 | -6.67% | 10 | 7 | OTM |
| 8 P | $0.75 | +114.29% | 1 | 66 | OTM |
| 8.5 P | $0.45 | -6.25% | 5 | 27 | ITM |
| 9 P | $0.75 | +25.00% | 4 | 238 | ITM |
| 9.5 P | $1.14 | +26.67% | 20 | 24 | ITM |
| 10 P | $1.05 | -12.50% | 4 | 11 | ITM |
| 10.5 P | $1.60 | +39.13% | 23 | 33 | ITM |
| 11 P | $1.50 | +0.00% | 4 | 2 | ITM |
| 11.5 P | $2.02 | -4.72% | 1 | 5 | ITM |
| 12 P | $2.47 | +0.00% | 1 | 1 | ITM |
| 12.5 P | — | — | 0 | 0 | ITM |
| 13 P | — | — | 0 | 0 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.